Artemisinin-resistant malaria prevalent across SE Asia.
FROM THE NEW ENGLAND JOURNAL OF MEDICINE
Artemisinin-resistant Plasmodium falciparum malaria remains uncontained. It is now "firmly established" in western Cambodia and Thailand, southern Vietnam, and eastern Myanmar and is emerging in southern Laos and northeastern Cambodia, according to a report published in the New England Journal of Medicine.
"Radical measures will be necessary in Southeast Asia to prevent resistance to artemisinins and their partner drugs from spreading to the Indian subcontinent and then to Africa," said Dr. Elizabeth A. Ashley of the Mahidol-Oxford Tropical Medicine Research Unit, affiliated with both Mahidol University in Bangkok, Thailand, and the University of Oxford, England, and her associates.
Artemisinin resistance was first reported in western Cambodia in 2008, and that is where resistance to previous first-line antimalarials also first emerged. "Defining the extent and severity of artemisinin resistance is essential for planning containment and elimination strategies," the investigators noted.
To map the current extent of artemisinin resistance, they performed an open-label, randomized trial at 15 sites in Cambodia, Thailand, Laos, Vietnam, Myanmar, Bangladesh, India, Nigeria, Kenya, and the Congo. Over a 2-year period, 1,241 patients aged 6 months to 65 years with acute, uncomplicated falciparum malaria were randomly assigned to receive either 2 mg or 4 mg of oral artesunate for 3 days, followed by a standard 3-day course of artemisinin-based combination therapy. Parasite clearance half-life was then determined using serial blood smears.
Longer parasite clearance half-life is associated with the organism's increasing resistance to the drug.
Parasite clearance half-life varied widely across the sites in Southeast Asia, from a low of 2 hours in Laos to a high of 7 hours in Thailand.
Slowly clearing infections, which were defined as a parasite clearance half-life of 5 hours or longer and indicated established resistance, were detected throughout mainland Southeast Asia, but they were not yet common in India or Africa.
Another measure of artemisinin resistance--the proportion of patients with parasitemia detectable on day 3--ranged from 0% in Kenya to 68% in eastern Thailand (N. Engl. J. Med. 2014 July 31 (doi: 10.1056/NEJMoal314981]).
Key clinical point: Malaria in newly arrived patients from Southeast Asia is likely to be drug resistant.
Major finding: Parasite clearance half-life was markedly slow (5 hours or longer), indicating resistance to artemisinins, across sites in Southeast Asia, but not in India or Africa.
Data source: An open-label, randomized clinical trial in which resistance to artemisinins was tracked across Southeast Asia, India, and Africa in 1,241 patients with acute uncomplicated falciparum malaria.
Disclosures: This study was supported by the U.K. Department for International Development, the Worldwide Antimalarial Resistance Network, the U.S. National Institute of Allergy and Infectious Diseases, and the Bill & Melinda Gates Foundation. Dr. Ashley and her associates reported no relevant conflicts of interest.
|Printer friendly Cite/link Email Feedback|
|Author:||Moon, Mary Ann|
|Publication:||Family Practice News|
|Date:||Aug 1, 2014|
|Previous Article:||Florida is site of first locally acquired chikungunya.|
|Next Article:||India, Africa undersampled.|